Lantern Pharma Inc. develops AI-driven precision oncology therapies and research platforms for cancer drug discovery. The company uses its proprietary RADR® platform to identify and advance small-molecule oncology candidates, including LP-300, LP-184 and LP-284, and develops STAR-001 for CNS cancers through Starlight Therapeutics, its wholly owned subsidiary.
Recurring news includes clinical-program updates for lung cancer, hematologic cancers, sarcomas and brain cancers; FDA and trial-design communications; financial results; and commercialization of AI tools such as withZeta.ai and predictBBB.ai. Company updates also cover subscription-based platform access, computational biology features and enterprise deployment for biomedical research and drug-development users.
Lantern Pharma (NASDAQ: LTRN) announced an enhanced collaboration with Georgetown University focusing on LP-184, a small molecule drug candidate for targeted treatment of certain solid tumors like prostate and pancreatic cancers. The initial phase yielded strong evidence of LP-184's efficacy, particularly in prostate cancer cells expressing PTGR1. Next steps involve expanding research to validate LP-184's mechanism of action and confirming genomic data which could lead to more personalized treatments. Lantern aims to streamline drug development costs using its RADR® AI platform.
Lantern Pharma (LTRN) has announced a collaboration with Fox Chase Cancer Center to advance the development of LP-184 for pancreatic cancer. The partnership aims to create a robust gene signature to enhance the efficacy of targeted therapies. CEO Panna Sharma emphasized the importance of collaborations in leveraging their RADR® A.I. platform for drug development. This agreement could streamline the path to clinical trials, potentially reducing costs and improving patient outcomes in a field where survival rates remain low. LP-184 is a next-generation alkylating agent currently in preclinical development.
Lantern Pharma (LTRN), a clinical-stage biopharmaceutical company, announced upcoming investor presentations for September 2020. CEO Panna Sharma will participate in several conferences, including the LD Micro 500 on September 1 at 2:40 p.m. ET, and the H.C. Wainwright Global Investor Conference on September 15 at 4:30 p.m. ET. The company utilizes its proprietary RADR® A.I. platform for oncology drug development, focusing on precision therapeutics. Interested investors can reach out for meetings through the provided contact information.
Lantern Pharma (LTRN), a clinical-stage biotechnology company, announced an upcoming interview with CEO Panna Sharma on The RedChip Money Report, airing on Bloomberg International on August 16, 2020, at 6 p.m. local time. The interview will cover the company’s A.I.-based drug discovery platform and ongoing clinical trials. Viewers can also access the segment on the Action Channel in the U.S. at 11 a.m. ET on the same day. Lantern Pharma focuses on using machine learning and genomics to develop targeted oncology drugs.
Lantern Pharma (NASDAQ: LTRN) announced its Q2 2020 financial results and updates on its R&D pipeline. The company reported a cash position of $23.8 million as of June 30, 2020, due to a successful IPO that raised $26.3 million. R&D expenses decreased to $157,023, while G&A expenses rose to $676,399 due to public company transition costs. The net loss was $833,422, up from $629,393 in Q2 2019. Key highlights include advancements in manufacturing capabilities, the RADR® platform exceeding 500 million data points, and ongoing clinical trials for LP-300 and LP-184.
Lantern Pharma (LTRN) will host a conference call on July 30, 2020, at 8:00 a.m. ET to discuss its financial and operational results for Q2 2020, ending June 30, 2020. Panna Sharma, the company's CEO, will lead the call alongside the management team. The call can be accessed via teleconference or online. A replay will be available for 30 days post-call. Lantern Pharma focuses on oncology therapeutics using its RADR® AI platform, aiming to improve patient outcomes through precision medicine by identifying suitable patient populations for its drug candidates.
Lantern Pharma (NASDAQ: LTRN) has entered agreements with top contract manufacturers to develop and produce oncology drugs LP-300 and LP-184. LP-300 targets non-small cell lung cancer in never-smokers and is approaching Phase 2 trials, with a significant market potential. Meanwhile, LP-184, aimed at genomically defined tumors, is set for Phase 1 trials in late 2021 or early 2022. The company leverages its RADR® A.I. platform, containing nearly 500 million data points, to enhance drug development and identify effective patient populations for its therapies.
Lantern Pharma (NASDAQ: LTRN) announced it has surpassed 450 million curated data points in its RADR® platform, aimed at enhancing personalized cancer therapies. This milestone supports the identification of specific drug responses in cancer patients and enables collaboration with partners to develop faster algorithms. Lantern's focus is on non-small cell lung cancer, ovarian cancer, and glioblastoma, improving outcomes and reducing costs. The company is on track to exceed 1 billion data points, significantly advancing its pipeline and drug development capabilities.
Lantern Pharma (NASDAQ: LTRN) announced two presentations for the AACR 2020 Virtual Annual Meeting, showcasing its AI platform RADR® in the development of LP-184, a drug candidate targeting specific tumors. The first abstract will detail LP-184's nanomolar potency and effectiveness against multi-drug resistant tumors. The second will explore a machine learning-derived genomic signature for predicting responses to LP-184. The company aims to leverage these findings for advancing their oncology drugs, enhancing treatment outcomes for patients.